Strong Progress and Financial Update from Celldex Therapeutics
August 8, 2025 - 01:36
Celldex Therapeutics has announced significant advancements in its pipeline, showcasing impressive results from its Phase 2 CSU study. The data revealed a profound and sustained complete response in patients, along with an improved quality of life measured seven months after the conclusion of barzolvolimab dosing. This breakthrough underscores the company's commitment to developing innovative therapies.
In addition to the CSU study results, Celldex is anticipating further data from ongoing Phase 2 studies of barzolvolimab targeting eosinophilic esophagitis (EoE) and chronic inducible urticaria (CIndU). Furthermore, results from a Phase 1 study of CDX-622 in healthy volunteers are expected in the latter half of 2025. These upcoming data releases are highly anticipated by stakeholders and could have significant implications for the company’s future direction and product offerings.
The financial results reported for the second quarter of 2025 reflect the company's strong execution and strategic focus on advancing its clinical programs, positioning it well for continued growth in the biopharmaceutical landscape.
MORE NEWS
July 6, 2026 - 01:10
Here is Why Yext (YEXT) is One of the Best Value Penny Stocks to Buy According to Hedge FundsYext Inc. (NYSE:YEXT) is gaining attention from hedge funds as one of the best value penny stocks to buy right now. The company recently reported its financial results for the first quarter of...
July 5, 2026 - 17:54
'It's a bull market': Wall Street sees more upside in stocks for the second half of 2026The stock market ended the first quarter on a high note, and major Wall Street firms are now forecasting continued momentum through the second half of the year. Analysts point to resilient...
July 4, 2026 - 21:25
Meet the High-Yield Dividend Stock That's Quietly Crushing the S&P 500 and Nasdaq. Here's Why There's Plenty of Room to Run.Most investors have never heard of this company, but its stock is up 30% year to date. That performance has quietly crushed both the S&P 500 and the Nasdaq composite, which have struggled to stay...
July 4, 2026 - 07:23
Micron Earned $24.67 Per Share Last Quarter. Its Dividend Is Still 15 Cents. Something Has to Give.Micron Technology is sitting on a pile of cash. The memory chip maker reported earnings of $24.67 per share for its most recent fiscal quarter, a staggering number that reflects the booming demand...